Check out the latest Prokaryotics buzz below.
Prokaryotics Receives STTR Phase II Award Supporting Development of a Mechanistically Novel Agent to Broadly Treat Fungal infections Caused by Drug-Resistant Candida, Aspergillus, and Rare Molds
Union, NJ -- August 15, 2023 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel antibiotics, announced today that it has been awarded its first antifungal STTR fast track to Phase 2 grant (R42AI179344-01) from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Please click here for more details.
U. S. Senators Menendez and Booker Stop by Prokaryotics Labs During Visit to Kean University
Union, NJ -- March 28, 2023 -- U. S. Senators Robert Menendez and Cory Booker visited Kean University on March 28 to celebrate the $18 million in federal funding they recently helped secure to support NJ Higher Education. After the presentations, Senators Booker and Menendez along with Kean President Lamont O. Repollet stopped by the Prokaryotics Labs for a tour and impromptu photoshoot with the Prokaryotics staff! Please click here for more details.
Prokaryotics Receives an NIH R01 Award to Develop Mechanistically Novel Cell Envelope Targeting Gram-negative Antibiotics
Union, NJ -- November 4, 2022 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel antibiotics, announced today that it has been awarded its first R01 grant (1R01 AI165740) valued at up to $3,394,311.00 from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The five-year agreement will fund antibiotic lead selection and pre-clinical optimization amongst a series of synthetic small molecule inhibitors targeting MsbA-mediated transport and biogenesis of lipopolysaccharide (LPS), an essential and unique element of the Gram-negative bacterial cell envelope. Please click here for more details.
Prokaryotics Receives SBIR Phase II Award Supporting Development of a Mechanistically Novel Combination Product to Treat Acinetobacter baumannii infections
Union, NJ -- August 27, 2022 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of mechanistically novel anti-infective drugs, announced today that it has been awarded an SBIR Phase II grant (1R44 AI165008-01A1) valued at up to $2,618,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The 3.5-year agreement will fund Prokaryotics’ goal of developing its mechanistically novel bacterial cell wall inhibitor in combination with clinically used or novel polymyxin cell envelope permeabilizers to treat life-threatening A. baumannii infections. Please click here for more details.
Prokaryotics Receives SBIR Phase IIB Award Supporting Preclinical Candidate Selection for β-lactam Potentiator Program
Union, NJ -- July 8, 2022 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel antibiotics, announced today that it has been awarded an SBIR Phase IIB grant (2R44 AI136213-04) valued at up to $2,972,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Please click here for more details.
Prokaryotics Receives Second R21 NIH Grant Supporting a Fifth Novel Antibiotic Program
Union, NJ -- June 28, 2022 -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel antibiotics, announced today that it has been awarded an R21 grant valued at up to $374,000 from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). Please click here for more details.
Prokaryotics Announces the Promotion of Holly Sutterlin, PhD, to Chief Operating Officer
Union, NJ -- June 1, 2022 -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of mechanistically novel anti-infective drugs, announced today the promotion of Dr. Holly Sutterlin from the dual roles as Director of Microbial Genetics and Director of Operations to Chief Operating Officer. Please click here for more details.
Prokaryotics announces that two patents covering novel compounds which restore the efficacy of commonly used β-lactams against MRSA have been issued by the U.S. Patent and Trademark Office
Union, NJ -- October 12, 2021 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that two patents, each covering a distinct series of novel compounds for both composition of matter and use as adjuvants to restore the efficacy of commonly used β-lactams against the dangerous superbug MRSA, have been issued by the U.S. Patent and Trademark Office. Please click here for more details.
Prokaryotics Advances Its Third SBIR-funded Antibiotic Research Program into Phase 2
Union, NJ -- August 16, 2021 -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has successfully advanced its third Small Business Innovation Research (SBIR R44AI145409-02) grant into Phase 2, a two year award valued at nearly $2 million dollars. Please click here for more details.
AiCuris selects Prokaryotics Inc. in its inaugural AiCubator Initiative to support Innovation in Infectious Disease
Union, NJ -- January 13, 2021 -- Prokaryotics Inc. announces that its bacterial cell envelope-targeting antibiotic program has been recognized by AiCuris as a novel and scientifically attractive resistance breaking opportunity of high priority. Please click here for more details.
Prokaryotics Receives $385,000 R21 NIH Grant Supporting A Fourth Novel Antibiotic Program
Union, NJ -- August 19, 2020 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has been awarded an R21 grant valued at up to $385,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Please click here for more details.
NJEDA Commission on Science, Innovation and Technology Announces Recipients of New Jersey SBIR/STTR Funding Support. Prokaryotics is proud to be among the 14 early stage innovation companies to receive this award.
Union, NJ -- June 18, 2020 -- Prokaryotics Inc, a privately-held biopharmaceutical company engaged in the discovery and development of novel antibiotics, announced today that it has been selected as one of fourteen life sciences companies in the Garden State to receive funding support by the New Jersey Commission on Science, Innovation and Technology. Please click here for more details.
Prokaryotics Receives $2.3 Million SBIR Award Supporting Its Immune Potentiation Program and Advances Two Additional SBIR-funded Antibiotic Programs into Phase 2 Lead Optimization
Union, NJ -- August 1, 2019 -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has been awarded its third Small Business Innovation Research (SBIR) grant valued at up to $2.3 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Please click here for more details.
New Hackensack Meridian Health- Center for Discovery and Innovation to receive $33.3 million grant from the NIH to develop a Center of Excellence for antibiotic discovery
Nutley, N.J -- May 10, 2019 -- The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) has selected infectious disease expert David S. Perlin, Ph.D. and Chief Scientific Officer of the new Hackensack Meridian Health-Center for Discovery and Innovation (CDI) to lead a major research effort aimed at developing novel antibiotics to overcome deadly bacteria in hospitals that have become resistant to current treatments. This grant reflects the core mission of the CDI to rapidly translate scientific innovations to address critical unmet clinical needs. Please click here for more details.
Prokaryotics Announces Exclusive Worldwide Licensing Agreement with MEDINA for New Antibiotic Compounds
Union, NJ -- April 14, 2019 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has entered into an exclusive licensing agreement with Fundación MEDINA, the not-for-profit Spanish foundation Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucia. Please click here for more details.
Prokaryotics Receives $2.3 Million SBIR Grant Supporting A Second Novel Antibiotic Program
Union, NJ -- September 13, 2018 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has been awarded its second Small Business Innovation Research Grant (SBIR) valued at up to $2.3 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Please click here for more details.
Prokaryotics Receives $2.5 Million SBIR Grant to Support Novel Antibiotic Program
Union, NJ -- March 08, 2018 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has been awarded a Small Business Innovation Grant (SBIR) valued at up to $2.5 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Please click here for more details.
Media Coverage
Union, NJ -- January 30, 2018 -- We appreciate Merck's support and, with our collaborators, are committed to taking on the global challenge of antibiotic resistance. Please click the link for details. Merck spinout grabs some assets and launches a quest for the Holy Grail in antibiotics R&D.
Prokaryotics Announces Licensing Agreement with Merck
Union, NJ -- January 25, 2018 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has entered into a licensing agreement with Merck, known as MSD outside the United States and Canada. Please click here for more details.
Novel Antibiotic Discovery Startup Commences Operations
Union, NJ -- January, 2017 -- Prokaryotics is a start-up biotechnology company resulting from licensing several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the head of the Antimicrobial Early Discovery Unit, to optimize a number of Merck’s early-stage programs.